{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T04:16:20Z","timestamp":1791778580986,"version":"4.3.4"},"reference-count":38,"publisher":"Portland Press Ltd.","issue":"1","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,2,1]]},"abstract":"<jats:p>Failure in the regulation of mTOR (mammalian target of rapamycin) appears to be critical to the pathogenesis of the inherited disorder tuberous sclerosis and the related lung disease LAM (lymphangioleiomyomatosis). Both diseases are caused by mutations of TSC1 or TSC2 (TSC is tuberous sclerosis complex) that impair GAP (GTPase-activating protein) activity of the TSC1\u2013TSC2 complex for Rheb, leading to inappropriate activity of signalling downstream of mTORC1 (mTOR complex 1). mTOR inhibitors are already used in a variety of clinical settings including as immunosuppressants, anticancer agents and antiproliferative agents in drug-eluting coronary artery stents. They also represent candidate therapies directed to the underlying molecular pathology in tuberous sclerosis and LAM. Phase I\/II clinical trials of the mTORC1 inhibitor rapamycin have demonstrated reduction in size of tuberous-sclerosis- and LAM-associated renal tumours (angiomyolipomas) and some evidence for reversible improvement in lung function in patients with LAM. A case series of tuberous-sclerosis-associated brain tumours were also reported to shrink during rapamycin therapy. An important, although variable, feature of the tuberous sclerosis phenotype is learning difficulty. Recent studies in mouse models carrying heterozygous Tsc2 mutations demonstrated improvement in memory and learning deficits following treatment with rapamycin. These promising pre-clinical and early human trials are being followed by larger-scale randomized control trials of mTOR inhibitors for treatment of renal, lung and brain manifestations of TSC1- and TSC2-associated disease.<\/jats:p>","DOI":"10.1042\/bst0370259","type":"journal-article","created":{"date-parts":[[2009,1,22]],"date-time":"2009-01-22T10:03:13Z","timestamp":1232618593000},"page":"259-264","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["Therapeutic targeting of mTOR in tuberous sclerosis"],"prefix":"10.1042","volume":"37","author":[{"given":"Julian\u00a0R.","family":"Sampson","sequence":"first","affiliation":[{"name":"Institute of Medical Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2009,1,20]]},"reference":[{"key":"2021111720042665600_B1","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/sj.ejhg.5201625","article-title":"Tuberous sclerosis","volume":"14","author":"Yates","year":"2004","journal-title":"Eur. J. Hum. Genet."},{"key":"2021111720042665600_B2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMra055323","article-title":"The tuberous sclerosis complex","volume":"355","author":"Crino","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"2021111720042665600_B3","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/0092-8674(93)90618-Z","article-title":"Identification and characterisation of the tuberous sclerosis gene on chromosome 16","volume":"75","author":"European Chromosome 16 Tuberous Sclerosis Consortium","year":"1993","journal-title":"Cell"},{"key":"2021111720042665600_B4","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.277.5327.805","article-title":"Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34","volume":"277","author":"van\u00a0Slegtenhorst","year":"1997","journal-title":"Science"},{"key":"2021111720042665600_B5","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1093\/hmg\/3.10.1833","article-title":"The tuberous sclerosis gene on chromosome 9q34 acts as a growth suppressor","volume":"3","author":"Green","year":"1994","journal-title":"Hum. Mol. Genet."},{"key":"2021111720042665600_B6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/ng0294-193","article-title":"Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients","volume":"6","author":"Green","year":"1994","journal-title":"Nat. Genet."},{"key":"2021111720042665600_B7","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/hmg\/7.6.1053","article-title":"Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products","volume":"7","author":"van\u00a0Slegtenhorst","year":"1998","journal-title":"Hum. Mol. Genet."},{"key":"2021111720042665600_B8","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.1038\/sj.onc.1204009","article-title":"The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination","volume":"19","author":"Benvenuto","year":"2000","journal-title":"Oncogene"},{"key":"2021111720042665600_B9","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1093\/hmg\/10.25.2899","article-title":"Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin","volume":"10","author":"Hodges","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"2021111720042665600_B10","doi-asserted-by":"crossref","first-page":"8313","DOI":"10.1074\/jbc.C500451200","article-title":"TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase","volume":"281","author":"Chong-Kopera","year":"2006","journal-title":"J. Biol. Chem."},{"key":"2021111720042665600_B11","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1093\/hmg\/6.11.1991","article-title":"The GAP-related domain of tuberin, the product of the TSC2 gene, is a target for missense mutations in tuberous sclerosis","volume":"6","author":"Maheshwar","year":"1997","journal-title":"Hum. Mol. Genet."},{"key":"2021111720042665600_B12","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0960-9822(03)00506-2","article-title":"Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb","volume":"13","author":"Tee","year":"2003","journal-title":"Curr. Biol."},{"key":"2021111720042665600_B13","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S1097-2765(03)00220-X","article-title":"Insulin activation of Rheb, a mediator of mTOR\/S6K\/4E-BP signaling, is inhibited by TSC1 and 2","volume":"11","author":"Garami","year":"2003","journal-title":"Mol. Cell"},{"key":"2021111720042665600_B14","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/ncb999","article-title":"Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins","volume":"5","author":"Zhang","year":"2003","journal-title":"Nat. Cell Biol."},{"key":"2021111720042665600_B15","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1101\/gad.1110003","article-title":"Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling","volume":"17","author":"Inoki","year":"2003","journal-title":"Genes Dev."},{"key":"2021111720042665600_B16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1042\/BJ20080281","article-title":"The TSC1\u2013TSC2 complex: a molecular switchboard controlling cell growth","volume":"412","author":"Huang","year":"2008","journal-title":"Biochem. J."},{"key":"2021111720042665600_B17","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/j.1523-1755.2004.00838.x","article-title":"Renal angiomyolipomata","volume":"66","author":"Bissler","year":"2004","journal-title":"Kidney Int."},{"key":"2021111720042665600_B18","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S0140-6736(03)13044-9","article-title":"Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma","volume":"361","author":"El-Hashemite","year":"2003","journal-title":"Lancet"},{"key":"2021111720042665600_B19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/rmed.2001.1206","article-title":"Lymphangioleiomyomatosis and tuberous sclerosis","volume":"96","author":"Hancock","year":"2002","journal-title":"Respir. Med."},{"key":"2021111720042665600_B20","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.1073\/pnas.97.11.6085","article-title":"Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis","volume":"97","author":"Carsillo","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021111720042665600_B21","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1164\/ajrccm.164.8.2104095","article-title":"Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangiomyomatosis","volume":"164","author":"Yu","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2021111720042665600_B22","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195122107.001.0001","article-title":"Tuberous Sclerosis Complex","author":"Gomez","year":"1999"},{"key":"2021111720042665600_B23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1017\/S0033291702007092","article-title":"Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex","volume":"33","author":"Joinson","year":"2003","journal-title":"Psychol. Med."},{"key":"2021111720042665600_B24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1469-8749.1994.tb11765.x","article-title":"Autistic behaviour and attention deficits in tuberous sclerosis: a population-based study","volume":"36","author":"Gillberg","year":"1994","journal-title":"Dev. Med. Child. Neurol."},{"key":"2021111720042665600_B25","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/brain\/awf124","article-title":"Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex","volume":"125","author":"Bolton","year":"2002","journal-title":"Brain"},{"key":"2021111720042665600_B26","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/adc.2003.026815","article-title":"The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex","volume":"89","author":"O'Callaghan","year":"2004","journal-title":"Arch. Dis. Child."},{"key":"2021111720042665600_B27","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.molmed.2007.06.003","article-title":"The tuberous sclerosis complex proteins: a GRIPP on cognition and neurodevelopment","volume":"13","author":"de\u00a0Vries","year":"2008","journal-title":"Trends Mol. Med."},{"key":"2021111720042665600_B28","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/hmg\/ddi190","article-title":"A mouse model of tuberous sclerosis 1 showing background specific early post-natal mortality and metastatic renal cell carcinoma","volume":"14","author":"Wilson","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"2021111720042665600_B29","doi-asserted-by":"crossref","first-page":"7934","DOI":"10.1158\/0008-5472.CAN-06-1740","article-title":"Tsc1 haploinsufficiency without mammalian target of rapamycin activation is sufficient for renal cyst formation in Tsc1+\/\u2212 mice","volume":"66","author":"Wilson","year":"2006","journal-title":"Cancer Res."},{"key":"2021111720042665600_B30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1203\/01.PDR.0000147727.78571.07","article-title":"Effects of rapamycin in the Eker rat model of tuberous sclerosis complex","volume":"57","author":"Kenerson","year":"2005","journal-title":"Pediatr. Res."},{"key":"2021111720042665600_B31","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/gcc.20118","article-title":"Efficacy of a rapamycin analog (CCI-779) and IFN-\u03b3 in tuberous sclerosis mouse models","volume":"42","author":"Lee","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"2021111720042665600_B32","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"2021111720042665600_B33","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1056\/NEJMc072500","article-title":"Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis","volume":"358","author":"Davies","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"2021111720042665600_B34","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.20784","article-title":"Rapamycin causes regression of astrocytomas in tuberous sclerosis complex","volume":"59","author":"Franz","year":"2006","journal-title":"Ann. Neurol."},{"key":"2021111720042665600_B35","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1523\/JNEUROSCI.0955-08.2008","article-title":"Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function","volume":"28","author":"Meikle","year":"2008","journal-title":"J. Neurosci."},{"key":"2021111720042665600_B36","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.21331","article-title":"Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex","volume":"63","author":"Zeng","year":"2008","journal-title":"Ann. Neurol."},{"key":"2021111720042665600_B37","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nm1788","article-title":"Reversal of learning deficits in a Tsc2+\/\u2212 mouse model of tuberous sclerosis","volume":"14","author":"Ehninger","year":"2008","journal-title":"Nat. Med."},{"key":"2021111720042665600_B38","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1128\/MCB.00289-08","article-title":"The TSC1\u2013TSC2 complex is required for proper activation of mTOR complex 2","volume":"28","author":"Huang","year":"2008","journal-title":"Mol. Cell. Biol."}],"container-title":["Biochemical Society Transactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/37\/1\/259\/546113\/bst0370259.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/37\/1\/259\/546113\/bst0370259.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T10:09:21Z","timestamp":1709978961000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article\/37\/1\/259\/65708\/Therapeutic-targeting-of-mTOR-in-tuberous"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,20]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2009,1,20]]},"published-print":{"date-parts":[[2009,2,1]]}},"URL":"https:\/\/doi.org\/10.1042\/bst0370259","relation":{},"ISSN":["0300-5127","1470-8752"],"issn-type":[{"value":"0300-5127","type":"print"},{"value":"1470-8752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,20]]}}}